Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Valeria Cervoni(University of Trieste), Valerio Iebba(University of Trieste), Carla Strina(Istituti Ospitalieri di Cremona), Alessandra Fontana(Università Cattolica del Sacro Cuore), Federica Gattazzo(Università Cattolica del Sacro Cuore), Lorenzo Morelli(Università Cattolica del Sacro Cuore), Giuseppe Curigliano(European Institute of Oncology), Manuela Milani(Humanitas University), Maria Rosa Cappelletti(University of Trieste)
Cited by 23
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k